Schedule 13D ownership disclosure

Corvus Pharmaceuticals Inc

Security class unavailable · CUSIP: 221015100

Event date: 2024-05-06

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
6,943,654
Percent of class
11.1000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000947871-24-000449
Form type
SC 13D/A
Filer
Corvus Pharmaceuticals, Inc.
CIK
CIK 1626971
Filed
May 08, 2024
Reporting period
May 06, 2024
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub